Quantum Genomics Stock

Quantum Genomics Equity

The The Equity of Quantum Genomics (ALQGC.PA) as of Aug 6, 2026 is -2.46 M EUR. In the previous year, The Equity was 436,700.00 EUR — a change of -662.38% (lower).

Equity

-2.46 MEUR

YoY

-662.38%

Last updated:

In 2026, Quantum Genomics's equity was -2.46 M EUR, a -662.38% increase from the 436,700.00 EUR equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Quantum Genomics Stock analysis

What does Quantum Genomics do? Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Quantum Genomics's Equity

Quantum Genomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Quantum Genomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Quantum Genomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Quantum Genomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Quantum Genomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Quantum Genomics stock

The Equity of Quantum Genomics is -2.46 M EUR in 2026.

The Equity of Quantum Genomics changed from 436,700.00 EUR to -2.46 M EUR, representing a -662.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Quantum Genomics since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Quantum Genomics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Quantum Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Quantum Genomics